Anixa's chimeric endocrine receptor T cell (CER T) targets the follicle stimulating hormone receptor, which is expressed on ovarian cells. The CER T will be evaluated for safety and efficacy at the Moffitt Cancer Center in patients with ovarian cancer.

Anixa holds an exclusive, worldwide license for the technology, which was developed at the Wistar Institute.

Anixa Biosciences, MolGenie announce SARS-CoV-2 protease inhibitor
Anixa Biosciences and its partner MolGenie have synthesized a compound that appears to be considerably more potent than nirmatrelvir at inhibiting the...

Anixa, OntoChem advance development of COVID-19 therapeutic
Anixa Biosciences and OntoChem are progressing to the next stage of development of an antiviral therapy for COVID-19.

Anixa, OntoChem identify new anti-SARS-CoV-2 compounds
Anixa Biosciences and OntoChem have identified 26 additional compounds that target the main protease inhibitors of SARS-CoV-2.

Anixa, OntoChem screen SARS-CoV-2 main protease inhibitors
Anixa Biosciences and OntoChem have completed in silico screening of four compounds that could function as SARS-CoV-2 main protease inhibitors.